TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34516312
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of intravenous Solumedrol every 8 hours for 7 days
Study: 35657079
Drug: Ibrutinib (560
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib (560 mg, orally once daily) plus bendamustine (90 mg/m²) and rituximab (375 mg/m²)
Study: 35657079
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus bendamustine (90 mg/m²) and rituximab (375 mg/m²)
Study: 35675356
Drug: Cochlear implants
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cochlear implants with additional visual cues
Study: 35675356
Drug: Cochlear implants
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cochlear implants alone
Study: 34852767
Drug: Lidocaine hydrochloride
Normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine hydrochloride (1.5 mg/kg induction and 2 mg/kg/h maintenance)
Study: 33032643
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ADT, WPRT, and SBRT boosts
Study: 34298438
Drug: Hydrocortisone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (30 mg oral)
Study: 33055122
Drug: Remote ischaemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote ischaemic conditioning (RIC) once daily for 30 days
Study: 33055122
Drug: Remote ischaemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote ischaemic conditioning (RIC) twice daily for 30 days
Study: 35775042
Drug: Dual-target group
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-target group (SASD bursa and LHBT sheath corticosteroid injection)
Study: 35775042
Drug: Single-target group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-target group (SASD bursa corticosteroid injection alone)
Study: 32621144
Drug: Routine interventional
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine interventional strategy in addition to optimal medical therapy
Study: 32444296
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (0.5 cm3 isotonic saline injection)
Study: 33794664
Drug: Topical ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ketorolac tromethamine 0.5%
Study: 34130783
Drug: Rehabilitation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation treatment based on ICF-CY Core Sets
Study: 33361100
Drug: Nitazoxanide (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitazoxanide (500 mg, three times daily for 5 days)
Study: 32979076
Drug: Walnut supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walnut supplementation (15% of total energy, ≈30–60 g/day)
Study: 32975164
Drug: MFS features
Normalized name: 3-MF
DrugBank: 3-Methylfentanyl (DB01571)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MFS features (graph, expected change trajectory line, alert, treatment suggestions)
Study: 32556354
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A injection (Group 1)
Study: 32556354
Drug: Radial extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial extracorporeal shock wave therapy (Group 2)
Study: 34351376
Drug: Oxycodone rescue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone rescue (oxycodone, 5 mg as second-line therapy)
Study: 34351376
Drug: Ibuprofen rescue
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen rescue (ibuprofen, 600 mg as second-line therapy)
Study: 34351376
Drug: Oxycodone rescue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone rescue
Study: 34351376
Drug: Ibuprofen rescue
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen rescue
Study: 34351376
Drug: Nonopioid users
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonopioid users (acetaminophen only or acetaminophen and ibuprofen)
Study: 35624408
Drug: Eliapixant 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eliapixant 10 mg
Study: 35624408
Drug: Eliapixant 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eliapixant 50 mg
Study: 35624408
Drug: Eliapixant 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eliapixant 200 mg
Study: 34581911
Drug: Viloxazine extended-release
Normalized name: viloxazine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viloxazine extended-release capsules (viloxazine ER; Qelbree™) 100-600 mg/day
Study: 34581911
Drug: Viloxazine extended-release
Normalized name: viloxazine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viloxazine extended-release capsules (viloxazine ER; Qelbree™)
Study: 34564938
Drug: Rosuvastatin 20
Normalized name: rosuvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 20 mg once daily for 180 days
Study: 32024944
Drug: Pharmacogenetics dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacogenetics dosing
Study: 34732500
Drug: Standard dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosing
Study: 32757545
Drug: As-usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: As-usual treatment (Control Group)
Study: 34348355
Drug: First-line drugs
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line drugs for neuropathic pain
Study: 32854094
Drug: Transgenic rice
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transgenic rice (80 g) administered orally for 20 weeks
Study: 32854094
Drug: Transgenic rice
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transgenic rice (5 g and 20 g) administered orally
Study: 32854094
Drug: Transgenic rice
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transgenic rice (80 g) administered orally
Study: 32493447
Drug: Hydroxychloroquine 200
Normalized name: hydroxychloroquine 200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine 200 mg tablet, 2 tablets daily for 1 to 3 months
Study: 33361495
Drug: Multicomponent training
Normalized name: meningococcus B, multicomponent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent training with traditional exercise and exergaming, twice a week for 12 weeks
Study: 34450687
Drug: Lateral injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral injection technique with a high G prime filler
Study: 34450687
Drug: Conventional technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional technique with a low G prime filler
Study: 35099294
Drug: Closed loop
Normalized name: Povidone Iodine 7.5% Topical application Liquid [OPERAND CLOSED LOOP PVP-I SCRUB]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed loop control (CLC) insulin delivery
Study: 33389313
Drug: 1.0-mg/kg/day Tripterygium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0-mg/kg/day Tripterygium wilfordii Hook F. (TwHF)
Study: 33389313
Drug: 1.5-mg/kg/day Tripterygium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5-mg/kg/day Tripterygium wilfordii Hook F. (TwHF)
Study: 34698813
Drug: Vi-polysaccharide Conjugate
Normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vi-polysaccharide Conjugate Vaccine
Study: 35427803
Drug: PDS 10‐mg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDS 10‐mg/ml
Study: 35427803
Drug: PDS 40‐mg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDS 40‐mg/ml
Study: 35427803
Drug: PDS 100‐mg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDS 100‐mg/ml
Study: 33217618
Drug: Monthly intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly intravitreal ranibizumab 0.5‐mg
Study: 35288513
Drug: Resistance Training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance Training (RT) + HMB supplementation (1500 mg daily)
Study: 35288513
Drug: Education +
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education + HMB supplementation (1500 mg daily)
Study: 33246482
Drug: PK-guided dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: PK-guided dosing of hydroxyurea
Study: 33246482
Drug: Standard weight-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard weight-based dosing of hydroxyurea (20 mg/kg/day)
Study: 35685676
Drug: Nalbuphine 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 0.2 mg/kg intravenously
Study: 35685676
Drug: Dexmedetomidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.5 μg/kg intravenously + Nalbuphine 0.2 mg/kg
Study: 33413212
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no professional oral care)
Study: 34478863
Drug: 5% topical
Normalized name: BP 5% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% topical benzoyl peroxide (BPO) gel applied for a total of 5 treatments
Study: 34478863
Drug: Blue light
Normalized name: Ocuvite Blue Light Mini Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blue light therapy (BLT), single 23‐minute treatment at 40 mW/cm2
Study: 34478863
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of BPO followed by BLT
Study: 34866029
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with low-intensity shockwave therapy (LiST) and tadalafil
Study: 32928237
Drug: Cisplatin-sensitized radiation
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-sensitized radiation therapy combined with pembrolizumab
Study: 33296389
Drug: combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination of both measures
Study: 35943743
Drug: Acupuncture (30-minute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (30-minute session after 50 mg/2 mL diclofenac sodium intramuscular injection)
Study: 32425222
Drug: Chlorpromazine (CPZ)
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorpromazine (CPZ) + standard treatment
Study: 34503983
Drug: Prednisolone monotherapy
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone monotherapy (4 months)
Study: 34503983
Drug: Prednisolone-itraconazole combination
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone-itraconazole combination (4 and 6 months)
Study: 34536666
Drug: Therapeutic touch
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic touch (TT) for 10 minutes daily for three consecutive days
Study: 33146811
Drug: modified endoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: modified endoscopic retrograde appendicitis therapy (mERAT)
Study: 33146811
Drug: antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: antibiotic treatment
Study: 35015806
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (20 µg/d)
Study: 35418080
Drug: 4 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 cycles of R-CHOP followed by 2 additional cycles of rituximab monotherapy for patients with negative interim PET/CT
Study: 32479794
Drug: Tepotinib 500
Normalized name: Tepotinib
DrugBank: Tepotinib (DB15133)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tepotinib 500 mg plus gefitinib 250 mg once daily (phase 2)
Study: 34650619
Drug: Tiotropium bromide
Normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tiotropium bromide powder inhalation (18 μg, inhalation, QD)
Study: 34650619
Drug: Formoterol fumarate
Normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Formoterol fumarate powder inhalation (12 μg, inhalation, BID) plus ambroxol hydrochloride tablets (60 mg, oral, TID)
Study: 33228459
Drug: Dexamethasone (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.6 mg/kg) administered on the third postoperative day with standard analgesia (ibuprofen and acetaminophen)
Study: 33228459
Drug: Standard analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard analgesia (ibuprofen and acetaminophen) without dexamethasone
Study: 35032643
Drug: Potassium nitrate
Normalized name: Potassium Nitrate
DrugBank: Potassium (DB14500)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Potassium nitrate (KNO3) 1300 mg (12.8 mmol)
Study: 36264446
Drug: Chinese-manufactured Glucophage®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese-manufactured Glucophage® (500 mg GIR tablet)
Study: 36264446
Drug: French-manufactured Glucophage®
Approvals — FDA: no, EMA: no, PMDA: no
Description: French-manufactured Glucophage® (500 mg GIR tablet)
Study: 32243492
Drug: Inclisiran 200
Normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Inclisiran 200 mg single dose
Study: 34454580
Drug: Angiotensin receptor
Normalized name: Angiotensin receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin receptor blockers (ARBs) at maximum tolerated daily dose
Study: 32208960
Drug: Paclitaxel (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (80 mg/m2, days 1, 8, and 15, every 4 weeks)
Study: 32208960
Drug: Paclitaxel with
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel with trastuzumab (PT; initially 8 mg/kg followed by 6 mg/kg, every 3 weeks)
Study: 32868580
Drug: Low-dose β-hydroxybutyrate
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose β-hydroxybutyrate (βHB) ketone monoester (KME; 252 mg·kg BW-1)
Study: 32868580
Drug: High-dose β-hydroxybutyrate
Normalized name: 4-hydroxybutyric acid
DrugBank: gamma-Hydroxybutyric acid (DB01440)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose β-hydroxybutyrate (βHB) ketone monoester (KME; 752 mg·kg BW-1)
Study: 33563102
Drug: 4% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% chlorhexidine gluconate followed by alcohol-based 1% chlorhexidine gluconate sanitizer lotion
Study: 33563102
Drug: Natural soap
Normalized name: Alba Natural Acnedote Soap Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural soap followed by alcohol-based 1% chlorhexidine gluconate sanitizer lotion
Study: 33563102
Drug: Waterless method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waterless method (natural soap followed by alcohol-based 1% chlorhexidine gluconate sanitizer lotion)
Study: 33563102
Drug: Two-stage method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-stage method (4% chlorhexidine gluconate followed by alcohol-based 1% chlorhexidine gluconate sanitizer lotion)
Study: 33789001
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of triheptanoin
Study: 33789001
Drug: Increased triheptanoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased triheptanoin dose levels
Study: 32464489
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 mg per day for 6 weeks)
Study: 35775284
Drug: 80% FiO2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80% FiO2 (treatment group)
Study: 34951042
Drug: ticagrelor‐aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ticagrelor‐aspirin
Study: 34951042
Drug: clopidogrel‐aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: clopidogrel‐aspirin
Study: 35522139
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapy including bevacizumab
Study: 35522139
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapy in patients with RAS/BRAF mutation
Study: 33187488
Drug: Being on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Being on re‐treatment for tuberculosis
Study: 35357078
Drug: Olaparib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib (300 mg twice daily, oral, tablets)
Study: 32989895
Drug: Control (Adper
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Adper Single Bond 2 without additional treatment)
Study: 34535330
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of remifentanil starting at 0.1 mcg/kg/min, increased to 1 mcg/kg/min if required
Study: 34535330
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus patient-controlled sedation analgesia (PCSA) with remifentanil infusion at 0.05 mcg/kg per minute and bolus of 0.1 mcg/kg with lock-out time of 3 minutes
Study: 34753154
Drug: Unbuffered lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unbuffered lidocaine needle‐free injection
Study: 32376628
Drug: ELX-02 (0.3-7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ELX-02 (0.3-7.5 mg/kg)
Study: 32376628
Drug: ELX-02 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: ELX-02 (20 and 100 μg/ml)
Study: 33501904
Drug: 360 mL
Normalized name: colostomy bags 10" 360 mL MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 360 mL of water
Study: 34923285
Drug: Etanercept 25
Normalized name: etanercept 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 25 mg plus methotrexate (MTX)
Study: 33155295
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training with supplemental oxygen (10 L/min)
Study: 33155295
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training with medical air (10 L/min)
Study: 36219061
Drug: Crisaborole 2%
Normalized name: CRISABOROLE 2% OINT,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crisaborole 2% ointment with weekly email surveys for 6 weeks, then monthly for 12 months (intervention group)
Study: 36219061
Drug: Crisaborole 2%
Normalized name: CRISABOROLE 2% OINT,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crisaborole 2% ointment without email surveys (control group)
Study: 33142117
Drug: Blockade of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blockade of compensatory neuronal innervation using LOXO-101, a Trk-NGF inhibitor.
Study: 32704168
Drug: Non-automated ML
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-automated ML approach
Study: 34101496
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (HD) of 61.6 Gy to the primary tumor
Study: 34101496
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose (SD) of 50.4 Gy to the tumor and regional lymph nodes
Study: 32331010
Drug: OLZ/SAM 10/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: OLZ/SAM 10/10 mg, 20/20 mg, 30/30 mg
Study: 34808678
Drug: Intra-Arterial Nimodipine
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-Arterial Nimodipine Infusion (IANI)
Study: 35710164
Drug: Fruit-rich diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruit-rich diet (FRD) with at least 4 servings of fruits daily
Study: 34170090
Drug: Monoclonal antibody
Normalized name: Monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibody against IBV M41 S1 protein
Study: 33121832
Drug: Topical tetracaine
Normalized name: tetracaine Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tetracaine applied every 30 minutes as needed for 24 hours
Study: 34942092
Drug: Second intravenous
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second intravenous immunoglobulin
Study: 32819191
Drug: Caffeine-nap (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine-nap (200 mg caffeine prior to a 30 min nap)
Study: 36380299
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT) plus usual care (UC)
Study: 33088309
Drug: Vaginal administration
Normalized name: Antiinflammatory products for vaginal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal administration of misoprostol (600 μg every 6 hours, maximum of 4 doses)
Study: 33088309
Drug: Sublingual administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual administration of misoprostol (600 μg every 6 hours, maximum of 4 doses)
Study: 33088309
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of misoprostol (600 μg every 6 hours, maximum of 4 doses)
Study: 33088309
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (Vaginal, Sublingual, Oral)
Study: 33753329
Drug: TAF/FTC 25/200
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAF/FTC 25/200 mg once daily (QD) on days 1 through 21; GSK3640254 200 mg QD added on days 15 through 21
Study: 33753329
Drug: TAF/FTC 25/200
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAF/FTC 25/200 mg once daily (QD) on days 1 through 21
Study: 33753329
Drug: GSK3640254 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3640254 200 mg QD
Study: 32700995
Drug: NaI (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaI (20 mg/kg, PO, 2 doses 72 hours apart; n = 211)
Study: 35670064
Drug: Individualized reverse‐calculation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized reverse‐calculation doses
Study: 33472996
Drug: Endostar combined
Normalized name: Menostar
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endostar combined with chemotherapy (gemcitabine plus cisplatin or docetaxel plus cisplatin)
Study: 33587443
Drug: Colchicine (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (0.6 mg daily)
Study: 36441433
Drug: Pioglitazone 15
Normalized name: pioglitazone 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 15 mg/day for 16 weeks